Jacqueline E. Shea - May 15, 2024 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)

Role: Chief Executive Officer, Director
Signature: /s/ Jacqueline E. Shea
Stock symbol: INO
Transactions as of: May 15, 2024
Transactions value $: -$100,874
Form type: 4
Date filed: 5/16/2024, 04:59 PM
Previous filing: May 13, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	INO	Common Stock	Options Exercise		+17.7K	+75.13%		41.4K	May 15, 2024	Direct	F1, F2
transaction	INO	Common Stock	Tax liability	-$101K	-7.72K	-18.66%	$13.07	33.6K	May 15, 2024	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	INO	Restricted Stock Unit	Options Exercise	$0	-17.7K	-33.33%	$0.00	35.5K	May 15, 2024	Common Stock	17.7K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 53,233 restricted stock units is as follows: 17,745 shares vested on May 15, 2024; 17,744 shares will vest on May 15, 2025; and 17,744 shares will vest on May 15, 2026. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both.
F2	Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.
F3	The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.